Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human LY6G6D Stable Cell Line

    [CAT#: S01YF-1023-PY199]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:
    Immune Checkpoint Cell Lines

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Product Information

    Target Family
    Immune Checkpoint
    Target Protein Species
    Human
    Host Cell Type
    HEK293;CHO-K1;RKO;SW620
    Target Classification
    Immune Checkpoint Cell Lines
    Target Research Area
    Metabolic Research
    Related Diseases
    Anemia, Nonspherocytic Hemolytic, Due To G6pd Deficiency; Glucosephosphate Dehydrogenase Deficiency
    Gene ID
    Human:58530
    UniProt ID
    Human:O95868

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    LY6G6D is a tumor-associated antigen that has shown potential in various applications for the treatment of colorectal cancer. It is a member of the MHC class III lymphocyte antigen 6G (LY6G) family and is considered an endogenous immunotoxin. LY6G6D has been found to inhibit anti-tumor immunity in colorectal cancer with proficient mismatch repair. T-cell engagers (TcEs) have been developed to target LY6G6D on cancer cells and CD3 on T cells, improving the treatment of metastatic solid tumors that are resistant to immune checkpoint inhibitors. LY6G6D has been identified as a selectively expressed colorectal cancer antigen that can be used to target a therapeutic T-cell response. It has demonstrated potent tumor cell killing and T cell activation in vitro and has shown tumor regressions in pre-clinical mouse models. LY6G6D can also modulate colorectal cancer through p38α MAPK and DNA methylation, and its expression is related to histological subtypes and epigenomic changes. Additionally, a novel anti-LY6G6D/CD3 T-cell-dependent bispecific antibody has been developed for the treatment of colorectal cancer, which exhibits potent antitumor activity in vitro and in vivo. Overall, LY6G6D shows promise as a target for immunotherapy in colorectal cancer.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human LY6G6D Stable Cell Line (S01YF-1023-PY199). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Taylor Garcia (Verified Customer)

    What is the significance of LY6G6D in colorectal cancer? Mar 26 2022

    chat Patrick Liam (Creative Biolabs Scientific Support)

    LY6G6D is a selectively expressed antigen in colorectal cancer (CRC) and can be targeted to activate cytotoxic T-cells, potentially leading to improved therapeutic efficacy. Mar 26 2022

    chat Casey Johnson (Verified Customer)

    How does LY6G6D expression influence chemotherapy resistance? Feb 23 2023

    chat Patrick Liam (Creative Biolabs Scientific Support)

    In metastatic CRC, hypermethylation of LY6G6D predicts resistance to FOLFOX first-line therapy, indicating that its cancer-specific hypomethylation and activation may be a tissue-specific mechanism of anti-tumor immunity. Feb 23 2023

    Published Data

    Fig.1 Enhanced LY6G6D protein expression was observed in metastatic cell lines, where the highest levels of P-STAT5 were detected.

    LY6G6D and CD15 were stained in RKO (MSI-H) and SW620 (MSS) cells, with green and red fluorescence, respectively. Basal activation of stat1, stat3, and stat5 was assessed in a panel of CRC cell lines in the lower right quadrant. In the lower left quadrant, the expression of P-STAT5, STAT5, P-ERK1/2, ERK1/2, and LY6G6D was examined via western blotting. Quantification of P-STAT5, P-ERK1/2, and LY6G6D relative to β-actin was performed in the lower right quadrant.

    Ref: Giordano, Guido, et al. "JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer." Journal of Experimental & Clinical Cancer Research 38.1 (2019): 1-11.

    Pubmed: 30670049

    DOI: 10.1186/s13046-018-1019-5

    Research Highlights

    Giordano, Guido; Pancio, Massimo. "MHC class III lymphocyte antigens 6 as endogenous immunotoxins: Unlocking immunotherapy in proficient mismatch repair colorectal cancer." WIREs mechanisms of disease, 2023.
    The majority of cancers, including colorectal cancer (CRC) with intact DNA mismatch repair, experience a suppressed immune response and resistance to immune checkpoint inhibitors. The MHC class III lymphocyte antigen 6G (LY6G) encodes glycosylphosphatidylinositol (GPI) proteins anchored to the membrane. LY6G proteins and snake venom neurotoxins contain a three-finger (3F) folding domain. Studies suggest that LY6 proteins, such as LY6G6D, may serve as effective tumor-associated antigens that can inhibit anti-tumor immunity in cancers with proficient mismatch repair. Therefore, they are referred to as MHC class III LY6G endogenous immunotoxins. In light of the discovery of LY6G6D as a tumor-associated antigen, T-cell engagers (TcEs) have been developed to simultaneously bind LY6G6D on cancer cells and CD3 on T cells, offering improved treatment options for individuals with metastatic solid tumors resistant to ICIs. This article presents a comprehensive understanding of how modifications in MHC class III genes influence antitumor immunity, and how this knowledge can be translated into effective therapies for patients who do not respond to standard immunotherapy.
    Giordano, Guido; Pancio, Massimo. "MHC class III lymphocyte antigens 6 as endogenous immunotoxins: Unlocking immunotherapy in proficient mismatch repair colorectal cancer." WIREs mechanisms of disease, 2023.
    Pubmed: 37818781   DOI: 10.1002/wsbm.1631

    Corrales, Leticia. et al. "LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager." Frontiers in immunology, 2022.
    Colorectal cancer (CRC) is a prevalent cancer affecting individuals globally and requires more advanced treatment approaches. Through examination of tumor genetic and molecular data, the researchers aimed to identify potential antigens unique to CRC cells and their potential for targeted cytotoxic T-cell therapy. Through this study, LY6G6D was identified as a promising tumor-specific antigen, primarily present in the microsatellite stable (MSS) subtype. A specialized anti LY6G6D/CD3 T cell engager (TcE) was developed and showed significant efficacy in killing CRC cells and activating T cells.
    Corrales, Leticia. et al. "LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager." Frontiers in immunology, 2022.
    Pubmed: 36159851   DOI: 10.3389/fimmu.2022.1008764

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare